Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.

2021-03

Lewis, Katharine L

Chin, Collin K

Manos, Kate

Casey, John

Hamad, Nada

Crawford, Julie

Ho, Shir-Jing

Issa, Samar

Grigg, Andrew P

Wood, Peter

Gandhi, Maher K

Do, Bryan

Nastoupil, Loretta

Hawkes, Eliza A

Cheah, Chan Y

BTK inhibitor

central nervous system

ibrutinib

lymphoma

novel

Journal Article

0000-0003-0549-5877

0000-0001-6880-2876

0000-0001-7929-1450

0000-0001-5743-3171

0000-0003-1000-5393

0000-0002-2094-3191

0000-0001-7988-1565

10.1111/bjh.16946

Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We analysed 33 patients who received ibrutinib, alone or with other therapies, for PCNSL (n = 9) or SCNSL (n = 24). The objective response rate was 58% (complete response 55%). The median progression-free survival and overall survival for patients with PCNSL were both 3·1 months; for SCNSL, 10·2 and 11·5 months respectively. Only one invasive fungal infection was observed, despite concurrent or recent use of dexamethasone 8-16 mg daily in 14 patients (42%). Ibrutinib has encouraging activity in these aggressive malignancies.

link

British Journal of Haematology 2020; 192(6): 1049-1053

British Journal of Haematology